Abstract
Glucagon-like peptide receptor-1 agonists have a key place in the hypoglycemic treatment of type 2 diabetes. The possibilities of their administration are now well outlined as well as their use in both the step-up and step-down an-tidiabetic therapy, the advantages and potential disadvantages of the already available oral version over the parenteral formulation, and the possible differentiation options for their basal insulin-combined variants. These issues are re-viewed in the article, but recent research on the drug group, monotherapeutic and combination products being under development are also briefly discussed. Attention is drawn on the importance of the early introduction of any of their long-acting derivates, the cardiorenal protective effect, powerful glycemic effect, weight loss promoting property and low hypoglycemic risk. It is important to keep doctors continuously informed about the latest results of this area as well as the correct patient education.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
